Anti-Aging & Longevity
PNC-27
p53-HDM2 binding peptide
Classification: Anticancer peptide (experimental)
Mechanism: Selective membrane disruption of cancer cells via HDM2 binding
Benefits: Selective cancer cell membrane disruption (preclinical)
Evidence tier: Preclinical · Availability: Experimental
Primary sources
- Sarafraz-Yazdi E et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci USA 2010. PMID 20080680
- Note: Preclinical evidence only — no published human clinical trials. Cited paper describes in-vitro or animal-model mechanism.
Loading interactive view…